Filtered By:
Condition: Thrombosis
Drug: Activase
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 351 results found since Jan 2013.
Intravenous Alteplase at 0.6 mg/kg for Unknown Onset Stroke with Prior Antithrombotic Medication: THAWS Randomized Clinical Trial
CONCLUSION: Alteplase appears more beneficial in patients with prior antithrombotic medication.PMID:35197420 | DOI:10.5551/jat.63337
Source: Journal of Atherosclerosis and Thrombosis - February 24, 2022 Category: Cardiology Authors: Masatoshi Koga Manabu Inoue Kaori Miwa Sohei Yoshimura Mayumi Fukuda-Doi Junya Aoki Koko Asakura Takao Kanzawa Masafumi Ohtaki Kenji Kamiyama Yusuke Yakushiji Shuichi Igarashi Ryosuke Doijiri Yasuhiro Ito Yasushi Takagi Makoto Sasaki Takanari Kitazono Kaz Source Type: research
Intravenous Thrombolytic Therapy for Treatment of Acute Ischemic Stroke in Patients Taking NOACs
Intravenous thrombolytic therapy with recombinant tissue plasminogen activator (alteplase) is the cornerstone of acute ischemic stroke reperfusion therapy and is associated with significant improvements in outcomes. Historically, a number of exclusion criteria for use of alteplase had been in place, but over the past 20 years, some of these have been eliminated (eg, age>80 years, seizures at stroke onset) or have become less stringent (eg, exclusion criteria may not strictly apply to recent vitamin K antagonist treatment if the patient has an international normalized ratio<1.7, and treatment may be administered in an...
Source: JAMA - February 22, 2022 Category: General Medicine Source Type: research
A practice game changer: Impact of tenecteplase for acute ischemic stroke in a multicenter quality improvement project
CONCLUSION: Institutions can safely transition from alteplase to tenecteplase as a thrombolytic of choice for AIS.PMID:35037028 | DOI:10.1093/ajhp/zxab482
Source: American Journal of Health-System Pharmacy : AJHP - January 17, 2022 Category: Drugs & Pharmacology Authors: Lydia Noh Felix Pham Lara Haddad Theresa Burkhard Laurie Paletz Marco Pech Maya Lewis Vicki Manoukian Konrad H Schlick Shlee Song Source Type: research
Outcomes and risk factors of perforating and non-perforating middle cerebral artery infarctions after intravenous thrombolysis
AbstractThe clinical symptoms of perforating arteries differ, and responses to intravenous thrombolytic therapy are heterogeneous. Here, we investigated the effect of intravenous thrombolytic therapy and the related factors influencing acute perforating and non-perforating middle cerebral artery infarctions. We analyzed 320 patients with acute middle cerebral artery infarction who received alteplase thrombolysis within 4.5 h of onset at two stroke centers from January 2016 to December 2019. Outcome measures included rates of a favorable functional outcome (modified Rankin Scale scores of 0–2), distribution of modified ...
Source: Journal of Thrombosis and Thrombolysis - January 14, 2022 Category: Hematology Source Type: research
Tenecteplase use in the management of acute ischemic stroke: Literature review and clinical considerations
CONCLUSION: Current clinical evidence shows that tenecteplase is not inferior to alteplase for the treatment of ischemic stroke and suggests that tenecteplase may have a superior safety profile. Furthermore, tenecteplase also has practical advantages in terms of its administration. This can potentially lead to a decrease in medication errors and improvement in door to thrombolytic time.PMID:35020806 | DOI:10.1093/ajhp/zxac010
Source: American Journal of Health-System Pharmacy : AJHP - January 12, 2022 Category: Drugs & Pharmacology Authors: Kirubel Hailu Chad Cannon Sarah Hayes Source Type: research
Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review
ConclusionsThe available evidence suggests that tenecteplase appears to be a better thrombolytic agent for acute ischemic stroke when compared to alteplase.
Source: International Journal of Emergency Medicine - January 4, 2022 Category: Emergency Medicine Source Type: research
Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase
AbstractDesmoteplase is a bat (Desmodus rotundus) saliva-derived fibrinolytic enzyme resembling a urokinase and tissue plasminogen activator. It is highly dependent on fibrin and has some neuroprotective attributes. Intravenous administration of desmoteplase is safe and well tolerated in healthy subjects. Plasma fibrinolytic activity is linearly related to its blood concentration, its terminal elimination half-life ranges from 3.8 to 4.92 h (50 vs. 90 μg/kg dose). Administration of desmoteplase leads to transitory derangement of fibrinogen, D-dimer, alpha2-antiplasmin, and plasmin and antiplasmin complex which normaliz...
Source: European Journal of Drug Metabolism and Pharmacokinetics - December 11, 2021 Category: Drugs & Pharmacology Source Type: research
